WO2000009073A2 - Blood-brain barrier therapeutics - Google Patents

Blood-brain barrier therapeutics Download PDF

Info

Publication number
WO2000009073A2
WO2000009073A2 PCT/US1999/018248 US9918248W WO0009073A2 WO 2000009073 A2 WO2000009073 A2 WO 2000009073A2 US 9918248 W US9918248 W US 9918248W WO 0009073 A2 WO0009073 A2 WO 0009073A2
Authority
WO
WIPO (PCT)
Prior art keywords
oligomer
gly
phe
group
trp
Prior art date
Application number
PCT/US1999/018248
Other languages
English (en)
French (fr)
Other versions
WO2000009073A3 (en
Inventor
Nnochiri N. Ekwuribe
Balasingam Radhakrishnan
Christopher H. Price
Wesley R. Anderson, Jr.
Aslam M. Ausari
Original Assignee
Nobex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corporation filed Critical Nobex Corporation
Priority to EP99943676A priority Critical patent/EP1105142A4/en
Priority to CA002340418A priority patent/CA2340418A1/en
Priority to KR1020017001888A priority patent/KR20010072472A/ko
Priority to MXPA01001694A priority patent/MXPA01001694A/es
Priority to AU56726/99A priority patent/AU772494B2/en
Priority to IL14103599A priority patent/IL141035A0/xx
Priority to BR9914280-5A priority patent/BR9914280A/pt
Priority to JP2000564577A priority patent/JP2002522463A/ja
Publication of WO2000009073A2 publication Critical patent/WO2000009073A2/en
Publication of WO2000009073A3 publication Critical patent/WO2000009073A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/US1999/018248 1998-08-14 1999-08-12 Blood-brain barrier therapeutics WO2000009073A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP99943676A EP1105142A4 (en) 1998-08-14 1999-08-12 THERAPEUTIC DRUGS CROSSING THE HEMATOENCEPHALIC BARRIER
CA002340418A CA2340418A1 (en) 1998-08-14 1999-08-12 Blood-brain barrier therapeutics
KR1020017001888A KR20010072472A (ko) 1998-08-14 1999-08-12 혈뇌장벽 치료제
MXPA01001694A MXPA01001694A (es) 1998-08-14 1999-08-12 Terapeutica para barrera hemoencefalica.
AU56726/99A AU772494B2 (en) 1998-08-14 1999-08-12 Blood-brain barrier therapeutics
IL14103599A IL141035A0 (en) 1998-08-14 1999-08-12 Blood-brain barrier therapeutics
BR9914280-5A BR9914280A (pt) 1998-08-14 1999-08-12 Produtos terapêuticos para barreirasangue-cérebro
JP2000564577A JP2002522463A (ja) 1998-08-14 1999-08-12 血液脳関門治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/134,803 1998-08-14
US09/134,803 US6703381B1 (en) 1998-08-14 1998-08-14 Methods for delivery therapeutic compounds across the blood-brain barrier

Publications (2)

Publication Number Publication Date
WO2000009073A2 true WO2000009073A2 (en) 2000-02-24
WO2000009073A3 WO2000009073A3 (en) 2000-06-29

Family

ID=22465087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018248 WO2000009073A2 (en) 1998-08-14 1999-08-12 Blood-brain barrier therapeutics

Country Status (11)

Country Link
US (5) US6703381B1 (US20040110735A1-20040610-C00004.png)
EP (1) EP1105142A4 (US20040110735A1-20040610-C00004.png)
JP (1) JP2002522463A (US20040110735A1-20040610-C00004.png)
KR (1) KR20010072472A (US20040110735A1-20040610-C00004.png)
CN (1) CN1323213A (US20040110735A1-20040610-C00004.png)
AU (1) AU772494B2 (US20040110735A1-20040610-C00004.png)
BR (1) BR9914280A (US20040110735A1-20040610-C00004.png)
CA (1) CA2340418A1 (US20040110735A1-20040610-C00004.png)
IL (1) IL141035A0 (US20040110735A1-20040610-C00004.png)
MX (1) MXPA01001694A (US20040110735A1-20040610-C00004.png)
WO (1) WO2000009073A2 (US20040110735A1-20040610-C00004.png)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196157A1 (en) * 1999-06-19 2002-04-17 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
WO2002066489A2 (de) * 2001-02-21 2002-08-29 Novosom Ag Amphotere sterole und deren verwendung zur herstellung von ph- sensitiven liposemen
WO2002092631A1 (en) * 2001-05-14 2002-11-21 The Horticulture And Food Research Institute Of New Zealand Limited Kinetic assay
WO2002098451A1 (en) 2001-06-04 2002-12-12 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003028764A1 (en) * 2001-10-03 2003-04-10 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
EP1638931A2 (en) * 2003-06-11 2006-03-29 Neuromolecular Inc. Method of targeting a therapeutic agent
US7119074B2 (en) 1999-09-13 2006-10-10 Nobex Corporation Treatment of cancers, tumors and malignancies using amphiphilic prodrugs
WO2007051306A1 (en) * 2005-11-04 2007-05-10 Bioxel Pharma Inc. New methods for the preparation of taxanes using chiral auxiliaries
US7446173B2 (en) 1998-10-16 2008-11-04 Biogen Idec Ma Inc. Polymer conjugates of interferon beta-1A and uses
US7527946B2 (en) 1998-10-16 2009-05-05 Biogen Idec Ma Inc., Interferon-beta-1a-immunoglobulin fusion proteins and uses
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
JP2010031284A (ja) * 2000-12-19 2010-02-12 California Inst Of Technology 包接複合体を含有する組成物
WO2010033195A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
WO2010100479A1 (en) * 2009-03-02 2010-09-10 School Of Pharmacy, University Of London Oral delivery of hydrophilic drugs to the brain
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8017733B2 (en) 2002-01-18 2011-09-13 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8252276B2 (en) 2002-09-06 2012-08-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US20130012443A1 (en) * 2011-07-07 2013-01-10 Regan Raymond F Methods of treatment of central nervous system hemorrhage using protoporphyrin ix-fe compounds
US8357377B2 (en) 2002-10-09 2013-01-22 Suzie Hwang Pun Cyclodextrin-based materials, compositions and uses related thereto
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US8883728B2 (en) 2005-02-23 2014-11-11 Aegis Therapeutics, Llc Intranasal administration of active agents to the central nervous system
US9040723B2 (en) 2008-07-14 2015-05-26 Biocon Limited Method of synthesizing a substantially monodispersed mixture of oligomers
CN106535944A (zh) * 2014-07-14 2017-03-22 Peg生物制药公司 聚合脑啡肽前药
US9682153B2 (en) 2008-09-19 2017-06-20 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. PEPTIDE INHIBITORS OF TAU AGGREGATION
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP4067370A1 (en) * 2009-05-08 2022-10-05 Chongxi Yu High penetration prodrug compositions of peptides and peptide related compounds
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles
US20220372172A1 (en) * 2003-05-01 2022-11-24 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DE60032255T2 (de) * 1999-10-04 2007-06-28 Nektar Therapeutics Al, Corp., Huntsville Polymer-stabilisierte neuropeptide
WO2005004792A2 (en) * 2003-06-24 2005-01-20 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
EP1569683B1 (en) * 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
KR101186210B1 (ko) * 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
SI1583562T1 (sl) * 2003-01-06 2011-10-28 Angiochem Inc AngioPep-1, sorodne spojine in njihove uporabe
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN102552917A (zh) 2003-08-13 2012-07-11 比奥孔有限公司 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂
BRPI0406605B8 (pt) * 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
CN102895666B (zh) * 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
DE102004009287A1 (de) * 2004-02-26 2005-09-15 Institut Für Neue Materialien Gem. Gmbh Amphiphile Nanopartikel
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
PL1791542T3 (pl) 2004-08-23 2015-11-30 Mannkind Corp Sole diketopiperazyny do dostarczania leków
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
CA2598666A1 (en) * 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
US20060211754A1 (en) * 2005-03-16 2006-09-21 Yu Ruey J Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
ATE502048T1 (de) * 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
CN101262890B (zh) * 2005-07-15 2015-08-26 安吉奥化学公司 抑肽酶多肽作为载体在药物缀合物中的用途
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20080004410A1 (en) * 2006-06-30 2008-01-03 Yu-Chin Lai Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same
FR2908414B1 (fr) 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
HUE027603T2 (en) * 2007-04-20 2016-10-28 Sigma-Tau Rare Disease Ltd Stable, recombinant adenosine deaminase
EP2157911A2 (en) * 2007-05-16 2010-03-03 Yeda Research And Development Co. Ltd. Assessment of blood-brain barrier disruption
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP2011500601A (ja) * 2007-10-12 2011-01-06 トランスモレキュラー， インコーポレイテッド 腫瘍の診断および処置のためのクロロトキシン薬剤の全身性投与
RU2518240C2 (ru) * 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
EP2300045A1 (en) 2008-05-15 2011-03-30 Transmolecular, Inc. Treatment of metastatic tumors
DK2570147T3 (da) 2008-06-13 2018-01-29 Mannkind Corp Tørpulverinhalator og system til lægemiddelindgivelse
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9147246B2 (en) 2009-08-18 2015-09-29 Ben-Gurion University Of The Negev Research And Development Authority Apparatus and method for analyzing stream of imaging data
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CA2788824C (en) 2010-02-04 2019-03-12 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
WO2011127256A1 (en) * 2010-04-07 2011-10-13 Board Of Regents Of The University Of Nebraska Protein-poly(2-oxazoline) conjugates for enhanced cellular delivery and transport across biological barriers
CN103097403B (zh) 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013057697A1 (en) 2011-10-19 2013-04-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CN105189540A (zh) 2012-12-10 2015-12-23 弗莱德哈钦森癌症研究中心 含脂质运载蛋白融合伴侣
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
WO2014174480A1 (en) 2013-04-24 2014-10-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3094643B1 (en) * 2014-01-15 2018-10-17 Fyziologicky ustav Akademie ved Ceske republiky, v.v.i. Lipidated peptides for lowering blood glucose
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256153A (en) 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4044196A (en) 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (fr) 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
JPS53116315A (en) 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4396606A (en) * 1979-11-05 1983-08-02 Addiction Research Foundation Novel polypeptide analgesics
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4698264A (en) 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4717566A (en) 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4622392A (en) 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
SE457326B (sv) 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US5093198A (en) 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
DE3721721C1 (de) 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
EP0307662A3 (en) * 1987-08-24 1990-07-25 Kabushiki Kaisha Vitamin Kenkyusyo Enkephalin analogs
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
JPH01308231A (ja) 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
US5055300A (en) 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
US5309633A (en) * 1990-12-13 1994-05-10 Claude Ricard Method and device for forming wiring harnesses
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
ES2194861T3 (es) 1992-11-12 2003-12-01 Sod Conseils Rech Applic Peptidos opiodes.
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US7067326B2 (en) * 1994-01-13 2006-06-27 The Trustees Of Columbia University In The City Of New York Synthetic receptors, libraries and uses thereof
SE9401596D0 (sv) 1994-05-06 1994-05-06 Astra Ab New compounds
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5641861A (en) 1995-06-07 1997-06-24 Torrey Pines Institute For Molecular Studies μopioid receptor ligands: agonists and antagonists
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US6440933B1 (en) * 1997-09-10 2002-08-27 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1105142A2 *

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527946B2 (en) 1998-10-16 2009-05-05 Biogen Idec Ma Inc., Interferon-beta-1a-immunoglobulin fusion proteins and uses
US7446173B2 (en) 1998-10-16 2008-11-04 Biogen Idec Ma Inc. Polymer conjugates of interferon beta-1A and uses
US9314534B2 (en) 1998-10-16 2016-04-19 Biogen Ma Inc. Polymer conjugates of interferon beta-1A and uses
EP1196157A4 (en) * 1999-06-19 2004-10-20 Nobex Corp AMPHIPHILE MEDICINE-OLIGOMER CONJUGATES WITH HYDROLYSABLE LIPOPHYLENE INGREDIENTS AND METHODS FOR THEIR PRODUCTION AND USE
EP1196157A1 (en) * 1999-06-19 2002-04-17 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
US7119074B2 (en) 1999-09-13 2006-10-10 Nobex Corporation Treatment of cancers, tumors and malignancies using amphiphilic prodrugs
US7807198B2 (en) 2000-12-19 2010-10-05 California Institute Of Technology Compositions containing inclusion complexes
JP2010031284A (ja) * 2000-12-19 2010-02-12 California Inst Of Technology 包接複合体を含有する組成物
US7968123B2 (en) 2000-12-19 2011-06-28 California Institute Of Technology Complexing agents for compositions containing inclusion complexes
US8277846B2 (en) 2000-12-19 2012-10-02 California Institute Of Technology Complexing agents for compositions containing inclusion complexes
JP2014210810A (ja) * 2000-12-19 2014-11-13 カリフォルニア インスティテュート オブテクノロジー 包接複合体を含有する組成物
US8092833B2 (en) 2000-12-19 2012-01-10 California Institute Of Technology Compositions containing inclusion complexes
US7407947B2 (en) 2001-02-21 2008-08-05 Novosom Ag Amphoteric sterols and the use thereof
WO2002066489A2 (de) * 2001-02-21 2002-08-29 Novosom Ag Amphotere sterole und deren verwendung zur herstellung von ph- sensitiven liposemen
WO2002066489A3 (de) * 2001-02-21 2003-01-03 Novosom Ag Amphotere sterole und deren verwendung zur herstellung von ph- sensitiven liposemen
WO2002092631A1 (en) * 2001-05-14 2002-11-21 The Horticulture And Food Research Institute Of New Zealand Limited Kinetic assay
WO2002098451A1 (en) 2001-06-04 2002-12-12 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1404360A1 (en) * 2001-06-04 2004-04-07 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
KR100930606B1 (ko) * 2001-06-04 2009-12-09 바이오콘 리미티드 폴리알킬렌 글리콜을 포함하는 칼시토닌 약물-올리고머접합체의 혼합물, 그의 용도 및 그의 제조방법
EP1404360B1 (en) * 2001-06-04 2010-01-06 Biocon Limited Monodisperse mixtures of calcitonin drug-oligomer conjugates comprising polyethylene glycol, uses thereof, and methods of making same
US7635686B2 (en) 2001-10-03 2009-12-22 Bioniche Life Sciences, Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
CN100352510C (zh) * 2001-10-03 2007-12-05 拜奥尼茨生命科学公司 可用于治疗的三甘醇胆甾烯基寡核苷酸
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
WO2003028764A1 (en) * 2001-10-03 2003-04-10 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
US8524660B2 (en) 2002-01-18 2013-09-03 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
US8017733B2 (en) 2002-01-18 2011-09-13 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
US8399431B2 (en) 2002-09-06 2013-03-19 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8389499B2 (en) 2002-09-06 2013-03-05 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US9550860B2 (en) 2002-09-06 2017-01-24 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8680202B2 (en) 2002-09-06 2014-03-25 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8609081B2 (en) 2002-09-06 2013-12-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8603454B2 (en) 2002-09-06 2013-12-10 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580242B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580243B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580244B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8252276B2 (en) 2002-09-06 2012-08-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8518388B2 (en) 2002-09-06 2013-08-27 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8314230B2 (en) 2002-09-06 2012-11-20 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8475781B2 (en) 2002-09-06 2013-07-02 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8404662B2 (en) 2002-09-06 2013-03-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8357377B2 (en) 2002-10-09 2013-01-22 Suzie Hwang Pun Cyclodextrin-based materials, compositions and uses related thereto
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US11845807B2 (en) * 2003-05-01 2023-12-19 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20220372172A1 (en) * 2003-05-01 2022-11-24 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
EP1638931A2 (en) * 2003-06-11 2006-03-29 Neuromolecular Inc. Method of targeting a therapeutic agent
EP1638931A4 (en) * 2003-06-11 2007-11-07 Neuromolecular Inc METHOD FOR TARGETING A THERAPEUTIC AGENT
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8535656B2 (en) 2004-09-07 2013-09-17 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US20120171152A1 (en) * 2004-09-07 2012-07-05 Kabanov Alexander V Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof
US9732147B2 (en) 2005-02-23 2017-08-15 Janssen Biotech, Inc. Method for delivering alpha-melanocyte stimulating hormone mimetibody composition comprising propylene glycol for intranasal administration to the central nervous system
US8883728B2 (en) 2005-02-23 2014-11-11 Aegis Therapeutics, Llc Intranasal administration of active agents to the central nervous system
US8207358B2 (en) 2005-11-04 2012-06-26 Accord Healthcare Ltd. Methods for the preparation of taxanes using chiral auxiliaries
WO2007051306A1 (en) * 2005-11-04 2007-05-10 Bioxel Pharma Inc. New methods for the preparation of taxanes using chiral auxiliaries
US9610360B2 (en) 2007-01-24 2017-04-04 Ceruliean Pharma Inc. Polymer drug conjugates with tether groups for controlled drug delivery
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US10143690B2 (en) 2007-03-12 2018-12-04 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9458166B2 (en) 2007-03-12 2016-10-04 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8946285B2 (en) 2007-03-12 2015-02-03 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8952032B2 (en) 2007-03-12 2015-02-10 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9827239B2 (en) 2007-03-12 2017-11-28 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9233167B2 (en) 2007-03-12 2016-01-12 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9233168B2 (en) 2007-03-12 2016-01-12 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10307416B2 (en) 2007-03-12 2019-06-04 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9512135B2 (en) 2007-03-12 2016-12-06 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8569343B2 (en) 2007-03-12 2013-10-29 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8440687B2 (en) 2007-03-12 2013-05-14 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9040723B2 (en) 2008-07-14 2015-05-26 Biocon Limited Method of synthesizing a substantially monodispersed mixture of oligomers
KR20110058783A (ko) * 2008-09-16 2011-06-01 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
KR101660996B1 (ko) 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
WO2010033195A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US9682153B2 (en) 2008-09-19 2017-06-20 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010100479A1 (en) * 2009-03-02 2010-09-10 School Of Pharmacy, University Of London Oral delivery of hydrophilic drugs to the brain
EP4067370A1 (en) * 2009-05-08 2022-10-05 Chongxi Yu High penetration prodrug compositions of peptides and peptide related compounds
US20130012443A1 (en) * 2011-07-07 2013-01-10 Regan Raymond F Methods of treatment of central nervous system hemorrhage using protoporphyrin ix-fe compounds
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles
EP3169406A4 (en) * 2014-07-14 2018-01-10 PEG Biosciences, Inc. Polymeric enkephalin prodrugs
CN106535944A (zh) * 2014-07-14 2017-03-22 Peg生物制药公司 聚合脑啡肽前药
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. PEPTIDE INHIBITORS OF TAU AGGREGATION

Also Published As

Publication number Publication date
JP2002522463A (ja) 2002-07-23
CN1323213A (zh) 2001-11-21
US6930090B2 (en) 2005-08-16
MXPA01001694A (es) 2002-04-08
EP1105142A2 (en) 2001-06-13
US20040102381A1 (en) 2004-05-27
AU772494B2 (en) 2004-04-29
US20040110735A1 (en) 2004-06-10
AU5672699A (en) 2000-03-06
EP1105142A4 (en) 2002-08-14
IL141035A0 (en) 2002-02-10
US6956051B1 (en) 2005-10-18
CA2340418A1 (en) 2000-02-24
US6703381B1 (en) 2004-03-09
WO2000009073A3 (en) 2000-06-29
KR20010072472A (ko) 2001-07-31
US6943148B1 (en) 2005-09-13
BR9914280A (pt) 2001-11-13

Similar Documents

Publication Publication Date Title
US6930090B2 (en) Methods of activating a receptor using amphiphilic drug-oligomer conjugates
AU2009292643B2 (en) Polymer conjugates of therapeutic peptides
JP5431874B2 (ja) ポリエチレングリコール−ｇｒｆ結合体の部位特異的調製方法
ES2397852T3 (es) Antagonistas y conjugados de péptidos CGRP
JP4272510B2 (ja) ポリアルキレングリコールを含むカルシトニン薬剤−オリゴマー抱合体の混合物、その使用、およびその製造方法
CA2301799C (en) Novel conjugates of opioids and endogenous carriers
EP1221975B1 (en) Polymer stabilized neuropeptides
JP2003104913A (ja) ポリアルキレングリコールを含む薬物−オリゴマー結合体の混合物、その使用及びその製造方法
JP2003516366A (ja) 両親媒性ポリマーとこれを含有するポリペプチドコンジュゲート
US6500918B2 (en) Conjugate comprising an antinociceptive agent covalently bonded to a blood component
US20030027995A1 (en) Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
TW200418451A (en) Modified carbamate-containing prodrugs and methods of synthesizing same
US20060199812A1 (en) Method of conjugating aminothiol containing molecules to vehicles
JP2004529886A (ja) 血液脳関門を通して鎮痛分子をベクター化することが可能なベクターに結合した前記鎮痛分子からなる化合物、及びそれらを含む医薬組成物
AU2002310278A1 (en) Mixtures of growth hormone drug-oligomer conjugates compromising polyalkylene glycol, uses thereof, and methods of making same
EP1167383A1 (en) Novel conjugates of opioids and endogenous carriers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812133.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 141035

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2340418

Country of ref document: CA

Ref document number: 2340418

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001694

Country of ref document: MX

Ref document number: 1020017001888

Country of ref document: KR

Ref document number: 56726/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999943676

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999943676

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017001888

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 56726/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017001888

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999943676

Country of ref document: EP